MOnitored supplementation of VItamin D in preterm infants (MOSVID trial): study protocol for a randomised controlled trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The pivotal role of vitamin D (vit D) in skeletal health is well known.

Registered on 15 March 2017.

Who Took Part

By PubMed's age tags, the people studied were infants.

Preterm infants born at 24-32 weeks of gestation will be recruited within the first 7 days of life.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The primary outcome measure will be the number of neonates with deficiency or excess levels of 25(OH)D at 40 ±2 weeks of PCA.

Additional 25(OH)D levels will be measured at birth, at 4 and 8 weeks of age, and/or at 35 and 52 ±2 weeks of PCA.

Secondary objectives will include the incidence of osteopenia, nephrocalcinosis and nephrolithiasis.

Serum parameters of calcium phosphorus metabolism will also be measured.

What Was Measured

The subject headings attached to it are Biomarkers, Bone Diseases, Metabolic, Cholecalciferol, Clinical Protocols, Dietary Supplements, Gestational Age and Incidence.

The authors tagged it with the keywords Osteopenia, Prematurity and Vitamin D.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Trials), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.